Josie Montegaard

Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study

Matthew S. Davids, Benjamin L. Lampson, Svitlana Tyekucheva et al. · The Lancet Oncology · 2021 · 102 citations

Medicine, Hematology, Pharmacology +11

Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome

Matthew S. Davids, Kerry A. Rogers, Svitlana Tyekucheva et al. · Blood · 2021 · 75 citations · Full text

Pharmacy, Pharmacotherapy, Translational Medicine +1

Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease

Matthew S. Davids, Christine E. Ryan, Benjamin L. Lampson et al. · Journal of Clinical Oncology · 2024 · 40 citations · Full text

Medicine, Oncology, Pharmacology +17

A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients

Matthew S. Davids, David C. Fisher, Svitlana Tyekucheva et al. · Leukemia · 2020 · 36 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Benjamin L. Lampson, Svitlana Tyekucheva, Jennifer L. Crombie et al. · Blood · 2019 · 31 citations

Medicine, Hematology, Pharmacology +10